期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

通心络胶囊对急性冠脉综合征患者氯吡格雷抵抗的影响 被引量：14

下载PDF
导出
摘要 目的评价通心络胶囊对急性冠脉综合征(ACS)患者氯吡格雷抵抗(CR)的影响。方法氯吡格雷抵抗患者84例,随机分为两组。A组44例,口服氯吡格雷75 mg,同时加用通心络胶囊4粒/次,每日3次。B组40例,每日口服氯吡格雷75 mg。C组为无氯吡格雷抵抗的患者35例,每日口服氯吡格雷75 mg。于服氯吡格雷前、服药后1周分别测定血小板聚集率抑制率。结果 3组患者在服用氯吡格雷前血小板聚集率无统计学意义(P>0.05),服药1周后,血小板聚集率A组为(21.5±3.9)%,B组为(28.1±5.7)%,C为组(17.9±4.7)%;血小板抑制率A组为(10.2±2.5)%,B组为(8.8±1.8)%,C组为(14.6±2.3),与治疗前比较有统计学意义(P<0.05)。其中,血小板聚集率C组<A组<C组,血小板抑制率C组>A组>C组(P<0.05)。结论通心络胶囊可以降低ACS患者氯吡格雷抵抗的发生。
作者 张萍 白如冰 马洪山
机构地区 山西省大同市第三人民医院
出处 《中西医结合心脑血管病杂志》 2010年第9期1037-1038,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 急性冠脉综合征 氯吡格雷 通心络胶囊 血小板聚集
分类号 R259 [医药卫生—中西医结合]
  • 相关文献

参考文献8

  • 1Lau WC, Gurhel PA, Watkins PB, et al. Contribution of hepat cytochrome P450 3A4 metabolic activity to the phenomenon clopidogrel resistance[J]. Circulation, 2004,109 : 166 - 171.
  • 2Paul A, Bliden KP, Hiatt BL, et al. Clopidogrel for eoronar stenting: Response variability,drug resistance,and the effect opretreatment platelet reactivity [J]. Circulation, 2003,107 : 2908 - 2913.
  • 3谭丽玲,贾三庆,王明生,李虹伟,王雷,赵敏,沈潞华,贾宁,孙志军.急性冠脉综合征患者氯吡格雷抵抗的影响因素[J].中国心血管病研究,2006,4(9):680-682. 被引量：14
  • 4Wenaweser P, Dorffler - Melly J , Imboden K,et al. Sten thrombosis is ,associated with an impaired response to antiplatele therapy [J]. J Coll Cardiol,2005,45: 1748 - 1752.
  • 5Jarvis B, Simpson K. Clopidogrel: A review of its use in the preven- tion of atherothrombosis[J]. Drugs, 2000,60 : 347 - 377.
  • 6Guthikonda S, Lev EI, Klieiman NS. Resistance to antiplatelet therapy[J]. Curt Cardiol Rep, 2005,7 (4):242 - 248.
  • 7Fontana P,Gaussem P,Aiach M,et al. P2Y12 H2 haplotype is associated wiperipheral arterial disease: A case- control study[J]. Circulation,2003,10(24) :2971 - 2973.
  • 8杨跃进,张健,吴永健,唐熠达,陈羲,阮英茆,尤士杰,刘坤申,陈纪林,高润霖,陈在嘉.通心络、卡维地洛、缬沙坦对兔急性心肌梗死晚期再灌注微血管内皮功能及完整性保护作用的对比[J].中国病理生理杂志,2006,22(7):1366-1369. 被引量：32

二级参考文献22

  • 1赵明中,高承梅,张宇洋.通心络胶囊对实验性心肌缺血再灌注损伤保护作用的实验研究[J].中国中医基础医学杂志,2000,6(1):36-38. 被引量：50
  • 2[1]Shamir RM,Salim Y,Ron JG P,et al.For the clopidogrel in unstable angina to prevent recurrent events trial (CURE) inverstigators.The Lancert,2001,358:527-533.
  • 3[2]Paul AG,Samara WM,Bliden KP.Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting:implications for thrombotic events and restenosis.Platelets,2004,15:95-99.
  • 4[3]Lau WC,Gurbel PA,Watkins PB,et al.Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.Circulation,2004,109:166-171.
  • 5[4]Paul A,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting:response variability,drug resistance,and the effect of pretreatment platelet reactivity.Circulation,2003,1.07:2908-2913.
  • 6[5]Muller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.Thromb Haemost,2003,89:783-787.
  • 7[6]Jaremo P,Lindahl TL,Fransson SG,et al.Individual variations of platelet inhibition after loading doses of clopidogrel.J Intern Med,2002,252:233-238.
  • 8[7]Soffer D,Moussa I,Harjai KJ,et al.Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv,2003,59:21-25.
  • 9[8]Matetzky S,Shenkman B,Guetta V,et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation,2004,109:3171-3175.
  • 10Yamamoto K,Ito H,Iwakura K,et al.Two different coronary blood flow velocity patterns in thrombolysis in myocardial infarction flow grade 2 in acute myocardial infarction:insight into mechanisms of microvascular dysfunction[J].J Am Coll Cardiol,2002,40(10):1755 -1760.

共引文献44

同被引文献109

引证文献14

二级引证文献60

中西医结合心脑血管病杂志
2010年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部